Vis enkel innførsel

dc.contributor.authorHelleberg, Bernt Harald
dc.contributor.authorEllekjær, Hanne
dc.contributor.authorRohweder, Gitta
dc.contributor.authorIndredavik, Bent
dc.date.accessioned2015-02-17T11:21:20Z
dc.date.accessioned2015-12-16T15:51:50Z
dc.date.available2015-02-17T11:21:20Z
dc.date.available2015-12-16T15:51:50Z
dc.date.issued2014
dc.identifier.citationBMC Neurology 2014, 14(201)nb_NO
dc.identifier.issn1471-2377
dc.identifier.urihttp://hdl.handle.net/11250/2367981
dc.description.abstractBackground: 10-40% of patients with acute ischemic stroke (AIS) suffer an early neurological deterioration (END), which may influence their long term prognosis. Multiple definitions of END exist, even in recently published papers. In the search for causes, various biochemical, clinical, and imaging markers have been found to be associated to END after AIS in some but not in other studies. The primary aim of this study is to assess the contribution of END to functional level at 3 months post stroke measured by modified Rankin Scale (mRS). Secondary aims are to identify factors and mechanisms associated with END and to define the prevalence, degree and timing of END in relation to stroke onset, and to compare Scandinavian Stroke Scale (SSS) and National Institute of Health Stroke Scale (NIHSS) based END-definitions. We hypothesized that END detected by changes in NIHSS and SSS (according to previously published criteria) at a threshold of 2 points indicate worsened prognosis, and that SSS is not inferior to NIHSS in predicting such a change. We further hypothesized that clinical deterioration has several causes, including impaired physiological homeostasis, vascular pathology, local effects and reactions secondary to the ischemic lesion, along with biochemical disturbances. Methods: Single-centre prospective observational study. Participants: Previously at home-dwelling patients admitted to our stroke unit within 24 hours after ictus of AIS are included into the study, and followed for 3 months. They are managed according to current procedures and national guidelines. A total of 368 patients are included by the end of the enrolment period (December 31st 2013), and the material will be opened for analysis by June 30th 2014. Frequent neurological assessments, continuous monitoring, and repeated imaging and blood samples are performed in all patients in order to test the hypotheses. Discussion: Strengths and weaknesses of our approach, along with reasons for the methods chosen in this study are discussed.nb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.titleMechanisms, predictors and clinical impact of early neurological deterioration: the protocol of the Trondheim early neurological deterioration studynb_NO
dc.typeJournal articlenb_NO
dc.typePeer revieweden_GB
dc.date.updated2015-02-17T11:21:20Z
dc.source.volume14nb_NO
dc.source.journalBMC Neurologynb_NO
dc.source.issue201nb_NO
dc.identifier.doi10.1186/s12883-014-0201-4
dc.identifier.cristin1200803
dc.description.localcode© 2014 Helleberg et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel